NOVALIQ PLANS TO FILE A MARKETING AUTHORISATION APPLICATION FOR CYCLASOL® IN THE E.U. FOR THE TREATMENT OF DRY EYE DISEASE IN JULY 2023
- CHMP determined CyclASol is eligible for a centralised procedure
- Novaliq has submitted a Letter of intent to file a Marketing Authorisation Application (MAA) in July 2023
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced its plans for filing a Marketing Authorisation Application (MAA) for CyclASol® (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED) in the European Union.